News

The National Multiple Sclerosis Society reported that the Patient-Centered Outcomes Research Institute (PCORI) has granted nearly $20 million in funding to four research projects assessing various multiple sclerosis (MS) therapies for their clinical effectiveness. Two of the grants will cover studies comparing disease-modifying treatments, looking to identify differences…

A new study  focused on an aspect of multiple sclerosis (MS) that is sometimes overlooked by researchers: progressive dwindling, or the tendency over time for people with MS to become increasingly frail and dependent on caregivers, with diminished energy and heightened disability. The report, “Progressive Dwindling in Multiple Sclerosis: An Opportunity…

Researchers at Queen’s University Belfast are studying how myelin might be repaired, in an attempt to reverse the damage caused by multiple sclerosis (MS). The more than £2 million, five-year research grant is jointly funded by  the Wellcome Trust, in its first Investigator Award for Northern Ireland, and by the BBSRC, the Biotechnology and Biosciences…

While the amount of vitamin D supplements, that should be taken by people with MS is not clear, the Scientific Advisory Committee on Nutrition (SACN), Vitamin D working group recently published a report recommending that everyone aged 4 and above should take 10 μg (400 IU) of vitamin D each day.

Gut bacteria and health have been topics of considerable scientific speculation in recent years, and the field of multiple sclerosis (MS) research is no exception. But what do we really know about MS and our intestinal inhabitants? A review, “Emerging Concepts on the Gut Microbiome and Multiple Sclerosis,” published in…

Sanofi Genzyme announced that the Government of Ontario has added Lemtrada (alemtuzumab) to the province’s Exceptional Access Program (EAP), opening coverage to the treatment for eligible patients with relapsing-remitting multiple sclerosis (RRMS). The program facilitates patient access to drugs not funded on the Ontario Drug Benefit (ODB) Formulary, or those…

Building on work began in stroke studies and applying it to multiple sclerosis, researchers in France report that an antibody they developed kept the blood-brain barrier intact in cellular and mice MS models despite the presence of inflammation, preventing immune cells from entering the brain. The key to understanding the study…

Women with multiple sclerosis (MS) and people diagnosed with the disease at a younger age are more likely to have a benign course of MS, remaining fully functional for decades after disease onset, according to researchers at the School of Medicine and Biomedical Sciences in New York. Disease modifying drugs were also found…

Low-quality unauthorized generic versions of approved multiple sclerosis (MS) drugs can expose patients to danger, both through their toxic properties and a lack of efficacy that allows the disease to progress, researchers reported in the study, “Clinical implications for substandard, nonproprietary medicines in multiple sclerosis: focus on fingolimod,” published…

Patients with relapsing multiple sclerosis (MS) are being recruited for a clinical trial evaluating an experimental monoclonal antibody called ublituximab, the National MS Society announced in a recent news release. The study, being conducted at seven U.S. sites, will enroll at least 24 patients, but this number can go up to 100. MS is considered to be…

Merck KGaA, Darmstadt, Germany recently announced that the European Medicines Agency (EMA) has accepted for review the Marketing Authorization Application (MAA) of the company’s investigational product Cladribine Tablets as a therapy for relapsing multiple sclerosis (RMS) in Europe. Cladribine is a synthetic antineoplastic agent able to suppress the immune system, causing relatively few…

A research project that aims to explore how astrocytes can be manipulated to stop or prevent neurodegeneration has received a grant from the National Stem Cell Foundation (NSCF). The project will be conducted by the The New York Stem Cell Foundation (NYSCF) Research Institute. The work developed by Dr. Valentina…

The Consortium of Multiple Sclerosis Centers (CMSC) has awarded Susan E. Bennett one of its highest honors, the Lifetime Achievement Award. Bennett, a clinical professor of rehabilitation science at the University at Buffalo and pioneer in the field of MS rehabilitation, was honored for her achievements in advancing care…

MediciNova recently reported that half of the 255 patients enrolled in a Phase 2b clinical trial (SPRINT-MS) exploring MN-166 (ibudilast) in progressive multiple sclerosis (MS) had completed the 96-week-long treatment. Interim data will be analyzed by the trial’s external Data Safety Monitoring Board later this year, with results…

MediciNova recently reported that half of the 255 patients enrolled in a Phase 2b clinical trial (SPRINT-MS) exploring MN-166 (ibudilast) in progressive multiple sclerosis (MS) had completed the 96-week-long treatment. Interim data will be analyzed by the trial’s external Data Safety Monitoring Board later this year, with results…

The Institute of Clinical and Economic Review (ICER), the nonprofit organization that released a preliminary draft last week intended to shape the Institute’s forthcoming report on the effectiveness and benefits of therapies for relapsing-remitting multiple sclerosis (RRMS), is made up of experts in healthcare policy from across the U.S. who, through the…

Individual health insurance coverage largely determines a multiple sclerosis (MS) patient’s access to disease modifying drugs in the United States, mainly because of the rising costs of newer medications and near-annual changes in insurance policy coverage, usually making such coverage more restrictive, researchers report.  These twin problems often leave MS patients relying on suboptimal therapies rather than those…

A recent study in the Journal of Medicinal Chemistry and Toxicology reported that the impact of disease-causing free radicals on the human body may be mitigated by wearing special, high-tech “Nanobionic” clothing for just a few hours a day. These clothes are designed to protect the body from…

A link indeed appears to exist between multiple sclerosis (MS) and unusual changes in the bacterial composition of the gut, according to researchers at Brigham and Women’s Hospital (BWH). In their study, “Alterations of the human gut microbiome in multiple sclerosis,” published in the journal Nature Communications,…

Endece was recently issued an additional U.S. patent for its lead investigational product, NDC-1308, being developed to induce remyelination in patients with multiple sclerosis (MS) and prevent disease progression. Currently in late preclinical development, NDC-1308 is designed to repair the myelin sheath of demyelinated axons (nerve fibers), a major cause…

A pilot study in patients with progressive multiple sclerosis (MS) found a steroid treatment of benefit by decreasing oxidative stress in the cerebrospinal fluid. The study, “One-time intrathecal triamcinolone acetonide application alters the redox potential in cerebrospinal fluid of progressive multiple sclerosis patients: a pilot study,” was published in the journal …

Despite the existence of several disease-modifying drugs for people with relapsing-remitting multiple sclerosis (RRMS), patients’ satisfaction plays a critical role in their adherence to treatment. Improving adherence should be a major concern in the clinic to prevent patients from evolving to more debilitating stages of the disease. A team of researchers in Germany report that side…

Disease-modifying therapies, a group of treatments for people with relapsing-remitting multiple sclerosis (RRMS), work to stabilize patients’ cognitive functions just as they do their physical symptoms. Research, conducted over the course of a year, also reported no differences between two types of DMTs, Gilenya (fingolimod) and Tysabri (natalizumab). The study, “…

Inflammation in a brain region called the hippocampus might explain why patients with multiple sclerosis (MS) suffer from depression far more often than patients with other chronic brain diseases. The findings, described in the report “Hippocampal Neuroinflammation, Functional Connectivity, and Depressive Symptoms in Multiple Sclerosis,” published in the…

Fecal samples from a group of people with relapsing-remitting multiple sclerosis (RRMS) showed evidence of a different gut microbiota than that found in healthy controls, and may be a non-genetic reason for the altered immune system responses seen in MS patients. The study, “Multiple sclerosis patients have…

One of the world’s most commonly used medications — the cholesterol-lowering drug simvastatin — was found to affect the immune system in a way that can be explored to treat inflammatory diseases such as multiple sclerosis (MS). Researchers have earlier noted that simvastatin, a cholesterol-lowering drug, is beneficial for MS…

Opinions voiced by multiple sclerosis (MS) patients as to what they most want from, and like in, an MS treatment differ widely, although delaying progression and relapses — and minimizing serious side effects — clearly score high, according to new research from the University of British Columbia in Canada. The study, “Quantitative…

Detecting brain atrophy in multiple sclerosis (MS) patients requires high quality scans, too expensive and complicated for routine clinical use. But this may change with a new software that simplifies the calculation of brain atrophy based on data from routine magnetic resonance images (MRI). The new tool and its benefits were recently described…

Biogen and AbbVie announced that the drug Zinbryta (daclizumab) has received marketing authorization by the European Commission, and is an approved treatment across most of Europe for adults with relapsing forms of multiple sclerosis (MS). Zinbryta is a self-administered, once monthly subcutaneous injection. “Clinical data showed Zinbryta significantly reduced relapses, 24-week…

A recent study analyzing the healthcare resource use and cost of H.P. Acthar Gel, an injectable drug used to manage multiple sclerosis (MS) relapse, demonstrated that the therapy is a viable alternative to plasmapheresis (PMP) and intravenous immunoglobin (IVIG). Annual direct healthcare costs encountered by MS patients in the U.S.